StrokeDx announced today that it closed a $5 million series seed prime funding round to support its stroke diagnostic technology.
Pasadena, California-based StrokeDx develops a rapid, portable and affordable stroke diagnostic device. It aims to deliver faster and more accurate results to healthcare providers to save crucial time in critical situations. The company plans to use the latest funds to support further clinical validation of its technology and expand its commercial efforts.
StrokeDx’s technology combines state-of-the-art engineering, novel algorithms and end-user design. It could enable portable, non-invasive, non-radiating cerebrovascular monitoring. According to a news release, the company believes the offering could provide a scalable solution to improve stroke outcomes for millions.
By utilizing portable devices, StrokeDx aims to address critical issues in healthcare accessibility and equity. The company says that early detection and rapid monitoring are key to improving survival rates and quality of life.
This funding marks the latest milestone for StrokeDx, which last fall won the grand prize in the MedTech Innovator 2023 Global Competition. To date, the company has brought in nearly $10 million. DigiTx Partners led the latest round, with Dr. David Kim, its managing director, joining StrokeDx’s board. Freeflow Ventures, along with other existing investors, also participated.
“Stroke affects millions globally, leading to significant mortality and long-term disability,” Alexander Ballatori, StrokeDx CEO and co-founder said. “This funding enables us to scale our detection and monitoring solution, empowering physicians and their patients with an effective tool for point-of-care cerebrovascular monitoring. Early intervention can significantly reduce the impact of stroke, shifting the focus from treatment to prevention.”
